Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer

The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial

“…12,13 Koizumiret et al [14][15][16][17] have found that the effective rate of SOX was 53%-59% in their clinic trails. A recent phase II clinical study 18 in Japan showed that nacG-SOX130 has demonstrated favorable clinical safety, as it resulted in high clinical and pathological responses without compromising surgical treatment in Stage III GC. Clinical RR was 88.2% (95% CI: 76.8-99.6) with CRs of (8.8%).…”

“…12,13 Koizumiret et al [14][15][16][17] have found that the effective rate of SOX was 53%-59% in their clinic trails. A recent phase II clinical study 18 There was no statistical difference between the protocol and the total number of medication cycles, indicating that preoperative neoadjuvant therapy combined with surgery and PAC can improve the long-term efficacy of patients compared with direct surgery plus PAC.…”